195 related articles for article (PubMed ID: 23098072)
41. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
42. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
43. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
[TBL] [Abstract][Full Text] [Related]
44. Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils.
Strassheim D; Asehnoune K; Park JS; Kim JY; He Q; Richter D; Kuhn K; Mitra S; Abraham E
J Immunol; 2004 May; 172(9):5727-33. PubMed ID: 15100319
[TBL] [Abstract][Full Text] [Related]
45. The TLR2 agonists lipoteichoic acid and Pam3CSK4 induce greater pro-inflammatory responses than inactivated Mycobacterium butyricum.
Gambhir V; Yildiz C; Mulder R; Siddiqui S; Guzzo C; Szewczuk M; Gee K; Basta S
Cell Immunol; 2012 Nov; 280(1):101-7. PubMed ID: 23298864
[TBL] [Abstract][Full Text] [Related]
46. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.
Erridge C; Kennedy S; Spickett CM; Webb DJ
J Biol Chem; 2008 Sep; 283(36):24748-59. PubMed ID: 18559343
[TBL] [Abstract][Full Text] [Related]
47. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
48. Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4+T cell stimulatory capacity.
Peiser M; Koeck J; Kirschning CJ; Wittig B; Wanner R
J Leukoc Biol; 2008 May; 83(5):1118-27. PubMed ID: 18252867
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro.
Teyssandier M; André S; Gupta N; Dasgupta S; Bayry J; Kaveri SV; Lacroix-Desmazes S;
Haemophilia; 2013 May; 19(3):399-402. PubMed ID: 23252683
[TBL] [Abstract][Full Text] [Related]
50. Microbial products stimulate human Toll-like receptor 2 expression through histone modification surrounding a proximal NF-kappaB-binding site.
Johnson CM; Tapping RI
J Biol Chem; 2007 Oct; 282(43):31197-205. PubMed ID: 17728249
[TBL] [Abstract][Full Text] [Related]
51. Trim13 Potentiates Toll-Like Receptor 2-Mediated Nuclear Factor
Huang B; Baek SH
Mol Pharmacol; 2017 Apr; 91(4):307-316. PubMed ID: 28087809
[TBL] [Abstract][Full Text] [Related]
52. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease.
Reynolds JM; Pappu BP; Peng J; Martinez GJ; Zhang Y; Chung Y; Ma L; Yang XO; Nurieva RI; Tian Q; Dong C
Immunity; 2010 May; 32(5):692-702. PubMed ID: 20434372
[TBL] [Abstract][Full Text] [Related]
53.
Su H; Zhang Z; Liu Z; Peng B; Kong C; Wang H; Zhang Z; Xu Y
J Biol Chem; 2018 Jun; 293(26):10287-10302. PubMed ID: 29739853
[TBL] [Abstract][Full Text] [Related]
54. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
55. Relevance of megalin receptor injury with nuclear factor-kappa B upregulation in acute kidney injury induced in rats.
Elshaer SS; Anwar HM
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29286200
[TBL] [Abstract][Full Text] [Related]
56. NOD1 cooperates with TLR2 to enhance T cell receptor-mediated activation in CD8 T cells.
Mercier BC; Ventre E; Fogeron ML; Debaud AL; Tomkowiak M; Marvel J; Bonnefoy N
PLoS One; 2012; 7(7):e42170. PubMed ID: 22848741
[TBL] [Abstract][Full Text] [Related]
57. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation.
Faure E; Thomas L; Xu H; Medvedev A; Equils O; Arditi M
J Immunol; 2001 Feb; 166(3):2018-24. PubMed ID: 11160251
[TBL] [Abstract][Full Text] [Related]
58. Mycobacterium tuberculosis MymA is a TLR2 agonist that activate macrophages and a T
Saraav I; Singh S; Pandey K; Sharma M; Sharma S
Tuberculosis (Edinb); 2017 Sep; 106():16-24. PubMed ID: 28802400
[TBL] [Abstract][Full Text] [Related]
59. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas.
Rydberg C; Månsson A; Uddman R; Riesbeck K; Cardell LO
Immunology; 2009 Sep; 128(1 Suppl):e600-11. PubMed ID: 19740321
[TBL] [Abstract][Full Text] [Related]
60. The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.
Peinado C; Kang X; Hardamon C; Arora S; Mah S; Zhang H; Ngolab J; Bui JD
Immunology; 2013 Jun; 139(2):265-74. PubMed ID: 23350962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
